Wall Street analysts expect that Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) will post earnings of ($0.16) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Cyclacel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.13). The business is expected to issue its next quarterly earnings results on Monday, February 11th.
According to Zacks, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.58). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.82) to ($0.58). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Monday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.01).
CYCC has been the topic of several recent research reports. Roth Capital initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, September 5th. They issued a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research raised shares of Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Friday, November 16th. LADENBURG THALM/SH SH started coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday, September 7th. They issued a “buy” rating and a $6.25 price target on the stock. ValuEngine raised shares of Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, HC Wainwright set a $7.00 target price on shares of Cyclacel Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Cyclacel Pharmaceuticals has a consensus rating of “Buy” and an average target price of $5.63.
A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after buying an additional 76,500 shares during the quarter. Renaissance Technologies LLC owned 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 5.62% of the company’s stock.
Shares of NASDAQ CYCC opened at $0.88 on Friday. Cyclacel Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $2.25.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Featured Article: Penny Stocks, What You Need To Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.